Cancer Council awards Melanoma Institute Australia researchers funding for ground-breaking cancer research projects
19 March 2019
Almost $9 million of new funding was awarded to 13 ground-breaking cancer research projects at the 2019 Cancer Council NSW Research Awards. The chosen world-class research teams are leading the charge towards a cancer free future by investigating new ways to diagnose and treat the disease.
Melanoma Institute Australia researchers, including Co-Medical Directors Professor Georgina Long and Professor Richard Scolyer, Associate Professor Matteo Carlino and Dr James Wilmott, have been awarded Cancer Council NSW Funding of $425,095 over the 2019-2021 funding period. Dr Wilmott attended the Gala Dinner on Thursday, March 14 to formally accept the grant on behalf of Melanoma Institute Australia.
Melanoma of the skin is the fourth most common cancer in Australia, with over 15,000 people expected to be diagnosed with the disease in 2019. Unlike other cancers of the skin, melanoma can spread throughout the body if not treated early. Termed ‘metastatic melanoma’ this advanced form of the disease kills one Australian every 5 hours.
Once melanoma has spread, the most effective treatment is immunotherapy. These immunotherapies release the brakes on the immune system to attack tumour cells. However, more than 40% of metastatic melanoma patients are not cured with these therapies, more for the other cancers. Therefore doctors need to be able to identify who is or isn’t likely to have benefit from the treatment. This means precious time is lost before alternative treatments are offered to those patients for whom immunotherapy won’t be effective.
Dr Wilmott is part of a team of researchers focused on finding treatments for the more than 40% of patients that are not cured with our best current therapies. In another study funded by Cancer Council NSW early career fellowship, the team of oncologists, pathologists, scientists and statisticians identified a set of immune related genes that are critical for a melanoma patient’s response to immunotherapies. The team have initially used these genes to successfully predict the effectiveness of immunotherapy in 105 patients with advanced melanoma.
In this project, the team aim to translate this information from the laboratory into the clinics of their oncology team, giving them the opportunity to test their methods in over 400 patients. They hope to verify their test can accurately identify patients who will respond to standard immunotherapies and the patients for who should be offered alternative treatment options.
This study could lead to the introduction of a simple test in the earliest stages of treatment planning for patients who are diagnosed with advanced melanoma. This would provide critical information for decision-making and ensure patients are offered the treatments most likely to be effective against their cancer.
This was adapted from the article originally published on Cancer Council NSW.
Next Steps for National Screening Program for Melanoma
On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.
Melanoma March Update
Melanoma March events have been cancelled. A Virtual March will be held on Sunday 29th March. Read this statement from MIA CEO Matthew Browne.
Saving lives this summer: 'Game On Mole!'
Thank you to the thousands of Aussies who bought ‘Game On Mole‘ t-shirts, took selfies, shared t-shirt pics on social media and started lifesaving conversations around sun safety and skin health.
PBS boost for melanoma patients
Melanoma patients now have greater access to subsidised immunotherapy thanks to additional treatments today being listed on the PBS.
An open letter to all young Australians
Brisbane couple Leon and Tamra Betts were, like thousands of others around Australia, on the couch watching MAFS when newlywed Natasha ran through her weekly beauty routine. When they heard the 26-year-old mention solarium use, they were shocked, and then saddened, prompting this open letter to all young Australians.
MIA leads world-class skin tumour pathology conference
Professor Richard Scolyer, Co-Medical Director of Melanoma Institute Australia, will welcome international attendees this weekend to a sold-out, two-day course on ‘Pigmented Lesions and Other Hot Topics in Dermatopathology’.
MAFS, it is time for a reality check on solariums.
It is time for a reality check on solariums.
They have no place in anyone’s beauty routine.
Community Fundraising January Wrap-Up
Throughout January our community created, hosted and participated in some amazing events, each of them helping us on our quest to reach zero deaths from melanoma.
Kyly Clarke urges Aussies to step up to save lives from melanoma
Australian television presenter, interior designer and mother Kyly Clarke has been announced as the new Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign Melanoma March.
Improving support for our patients across Australia.
Melanoma Institute Australia has recently partnered with three other organisations to boost support for melanoma patients and their carers across Australia.
Boost to melanoma support in WA
Melanoma patients and their families across Western Australia will benefit from strengthened and expanded services with the merging of melanomaWA and Melanoma Institute Australia.
New Test to Predict Primary Melanoma Progression
Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.
Community Fundraising December Wrap-Up
We are extremely grateful for our community fundraisers, who, even in this difficult time, have given up their time and effort to fundraise so we can continue to work towards our goal of zero deaths from melanoma.
Two melanoma treatments approved for PBS listing
Melanoma patients are set to benefit from subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients.
Immunotherapy: the decade's biggest health advance
An informative article on how immunotherapy is revolutionising cancer treatment, written by Jill Margo and featured in the Australian Financial Review.
Boost to Melanoma Services in the Riverina
Melanoma patients and their families in the Riverina will benefit from strengthened and sustained melanoma services with the merger of the Amie St Clair Melanoma Trust and Melanoma Institute Australia.
Winner of the SunSafe Student Ambassador Program announced
Belmont High School at Lake Macquarie has been announced winner of the 2019 SunSafe Student Ambassador Program video competition.
Community Fundraising November Wrap-Up
It’s time again to say thank you to our amazing community fundraisers!
MIA & MPA Patient Information Evening videos now available
Videos of the sessions at the recent Patient Information Evening co-hosted by Melanoma Institute Australia (MIA) and Melanoma Patients Australia (MPA) are now available for viewing.
MIA shines in poster session
MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.